Exhibit 16.1
July 19, 2017
Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549-7561
Dear Sirs/Madams:
We have read Item 4.01 of Daré Bioscience, Inc.’s Form 8-K dated July 19, 2017, and have the following comments:
(1) | we agree with the statements made within Item 4.01(a); and |
(2) | we have no basis on which to agree or disagree with the statements made in Item 4.01(b). |
Yours truly,
/s/ DELOITTE & TOUCHE LLP